ZAI LAB LIMITED Increase (Decrease) in Notes Receivable, Current
ZAI LAB LIMITED (ZLAB) reported Increase (Decrease) in Notes Receivable, Current of -$9.04 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInNotesReceivableCurrent · last filed 2026-08-06
- ZAI LAB LIMITED increase (decrease) in notes receivable, current for the quarter ending 2026-06-30 was -$4.63M.
- ZAI LAB LIMITED increase (decrease) in notes receivable, current for the quarter ending 2026-03-31 was -$4.41M, a 164.05% decline year-over-year.
- ZAI LAB LIMITED increase (decrease) in notes receivable, current for the quarter ending 2025-12-31 was -$7.51M.
- ZAI LAB LIMITED increase (decrease) in notes receivable, current for the quarter ending 2025-09-30 was $8.61M, a 20.90% decline year-over-year.
- ZAI LAB LIMITED increase (decrease) in notes receivable, current for fiscal 2025 was $7.72M.
- ZAI LAB LIMITED increase (decrease) in notes receivable, current for fiscal 2024 was -$1.76M.
- ZAI LAB LIMITED increase (decrease) in notes receivable, current for fiscal 2023 was -$2.35M, a 219.03% decline from fiscal 2022.
- ZAI LAB LIMITED increase (decrease) in notes receivable, current for fiscal 2022 was $1.98M, a 73.06% decline from fiscal 2021.
| Period end | Increase (Decrease) in Notes Receivable, Current 3 month | Increase (Decrease) in Notes Receivable, Current 6 month | Increase (Decrease) in Notes Receivable, Current 9 month | Increase (Decrease) in Notes Receivable, Current 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$9.04M 10-Q · filed 2026-08-06 | -$16.55M derived: sum of 3 quarters · filed 2026-08-06 | -$7.94M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$4.41M 10-Q · filed 2026-05-07 | -$11.92M derived: sum of 2 quarters · filed 2026-05-07 | -$3.31M derived: sum of 3 quarters · filed 2026-05-07 | -$3.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$7.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.10M derived: sum of 2 quarters · filed 2026-02-26 | $831.00K derived: sum of 3 quarters · filed 2026-08-06 | $7.72M 10-K · filed 2026-02-26 |
| 2025-09-30 | $8.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $8.34M derived: sum of 2 quarters · filed 2026-08-06 | $15.22M 10-Q · filed 2025-11-06 | $560.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$274.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $6.61M 10-Q · filed 2026-08-06 | -$8.05M derived: sum of 3 quarters · filed 2026-08-06 | $2.84M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $6.88M 10-Q · filed 2026-05-07 | -$7.78M derived: sum of 2 quarters · filed 2026-05-07 | $3.11M derived: sum of 3 quarters · filed 2026-05-07 | -$4.12M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$14.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$3.77M derived: sum of 2 quarters · filed 2026-02-26 | -$11.00M derived: sum of 3 quarters · filed 2026-02-26 | -$1.76M 10-K · filed 2026-02-26 |
| 2024-09-30 | $10.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.66M derived: sum of 2 quarters · filed 2025-11-06 | $12.90M 10-Q · filed 2025-11-06 | -$5.01M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$7.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.01M 10-Q · filed 2025-08-07 | -$15.90M derived: sum of 3 quarters · filed 2026-02-26 | -$13.05M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $9.24M 10-Q · filed 2025-05-08 | -$8.68M derived: sum of 2 quarters · filed 2026-02-26 | -$5.83M derived: sum of 3 quarters · filed 2026-02-26 | -$1.71M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$17.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$15.07M derived: sum of 2 quarters · filed 2026-02-26 | -$10.95M derived: sum of 3 quarters · filed 2026-02-26 | -$2.35M 10-K · filed 2026-02-26 |
| 2023-09-30 | $2.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $6.96M derived: sum of 2 quarters · filed 2024-11-12 | $15.56M 10-Q · filed 2024-11-12 | $13.68M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $4.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $12.71M 10-Q · filed 2024-08-06 | $10.83M derived: sum of 3 quarters · filed 2025-02-27 | $11.06M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $8.60M 10-Q · filed 2024-05-08 | $6.71M derived: sum of 2 quarters · filed 2025-02-27 | $6.94M derived: sum of 3 quarters · filed 2025-02-27 | $7.06M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$1.66M derived: sum of 2 quarters · filed 2025-02-27 | -$1.54M derived: sum of 3 quarters · filed 2025-02-27 | $1.98M 10-K · filed 2025-02-27 |
| 2022-09-30 | $228.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $348.00K derived: sum of 2 quarters · filed 2023-11-07 | $3.86M 10-Q · filed 2023-11-07 | $11.20M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $120.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $3.63M 10-Q · filed 2023-08-07 | $10.97M derived: sum of 3 quarters · filed 2024-02-27 | $10.97M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $3.51M 10-Q · filed 2023-05-09 | $10.85M derived: sum of 2 quarters · filed 2024-02-27 | $10.85M derived: sum of 3 quarters · filed 2024-02-27 | $10.85M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $7.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $7.33M derived: sum of 2 quarters · filed 2024-02-27 | $7.33M derived: sum of 3 quarters · filed 2024-02-27 | $7.33M 10-K · filed 2024-02-27 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |